Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer: A Prospective, Single-Arm, Phase II Study

NCT07663513 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07663513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07663513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer: A Prospective, Single-Arm, Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
April 30, 2029
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancers